Bromocriptine

Bromocriptine

SCHEMBL25297

CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2DRD3DRD4

The experimentally established mechanism targets of Bromocriptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 known ✓ P35462 5/20 1.00
DRD2 known ✓ P14416 4/20 1.00
DRD4 known ✓ P21917 1/20 1.00
KDM4E B2RXH2 10/20 1.00
MAPT P10636 10/20 1.00
CYP3A4 P08684 9/20 1.00
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
CYP2C9 P11712 7/20 1.00
ABCB1 P08183 7/20 1.00
LMNA P02545 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
ADRA2A P08913 5/20 1.00
DRD1 P21728 5/20 1.00
CYP2C19 P33261 4/20 1.00
ADRA2B P18089 4/20 1.00
ADRA2C P18825 4/20 1.00
ADRA1D P25100 4/20 1.00
HTR2A P28223 4/20 1.00
HTR2C P28335 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromocriptine SCHEMBL186901 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL29414631 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL29364057 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL8032620 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL19276395 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL9526627 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL23468147 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL3134319 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL3134317 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
Bromocriptine SCHEMBL11890530 1.00 KDM4E (1.00) KDM4EMAPTCYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 47458 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
CN-122075697-A SFMBT2 gene and application of bromocriptine in repairing damaged cartilage and preventing and treating osteoarthritis 2026-05-26 CN claimed
WO-2026106939-A1 IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION VANDERBILT UNIVERSITY (US) 2026-05-21 WO claimed
US-20260131140-A1 MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION VANDERBILT UNIV (US) 2026-05-14 US claimed
US-12616693-B2 Bromocriptine formulations VEROSCIENCE LLC (US) 2026-05-05 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-20260092141-A1 SERIES OF POLYMERS HAVING PROPERTIES OF ACID-SENSITIVE DEGRADATION AND TEMPERATURE SENSITIVITY AND DRUG LOADING COMPOSITION THEREOF NANJING FANTAI CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE (CN) 2026-04-02 US claimed
EP-4717276-A2 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER University of Canberra (AU) 2026-04-01 EP claimed
EP-4712959-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF Mirum Pharmaceuticals, Inc. (US) 2026-03-25 EP claimed
EP-0041030-B1 COMPOSITIONS FOR TOPICAL USE CONTAINING ERGOT OR VINCA ROSEA ALKALOIDS FOR TREATMENT OF HYPERSEBORRHOEA, AND THEIR PREPARATION PIERRE FABRE S.A. (FR) 1984-03-14 EP claimed
US-4411882-A AN ERGOT ALKALOID AND A POLYALKOXYALKYLENE STEROL ETHER SANDOZ LTD. (CH) 1983-10-25 US claimed
US-4384975-A SOLVENT REMOVAL FROM AN OIL IN WATER EMULSION CONTAINING SODIUM OLEATE OR POTASSIUM OLEATE SANDOZ, INC. (US) 1983-05-24 US claimed
US-4382921-A Method for treatment of psoriasis SERONO PHARMACEUTICAL PARTNERS A MA LIMITED PARTNERSHIP 1983-05-10 US claimed
US-4366145-A Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation SANDOZ, INC. (US) 1982-12-28 US claimed
EP-0041030-A1 Compositions for topical use containing Ergot or Vinca Rosea alkaloids for treatment of hyperseborrhoea, and their preparation PIERRE FABRE S.A. (FR) 1981-12-02 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
US-4225605-A Ergolene or ergoline compounds for treating congestive heart failure SANDOZ LTD. (CH) 1980-09-30 US claimed
US-4202897-A IMIDAZON2,1-AE ISOINDOLES AND ISOQUINOLINES SANDOZ, INC. (US) 1980-05-13 US claimed
US-4166800-A Processes for preparation of microspheres SANDOZ, INC. (US) 1979-09-04 US claimed